Azelastine + Fluticasone Propionate

This medicine combines two well-known allergy drugs in one intranasal spray, referred to in trials by the code MP-AzeFlu. ^[1] Azelastine hydrochloride is an antihistamine that blocks the effect of histamine, while fluticasone propionate is a glucocorticoid (corticosteroid) that broadly reduces inflammation in the nasal lining. ^[1] Delivering both from a single spray targets allergy symptoms through two mechanisms at once.

It is used to treat moderate to severe allergic rhinitis, including seasonal (hay fever) and year-round forms, in adults and children. Reviews note that many people with more severe allergic rhinitis are not adequately controlled by a single medicine, which is the rationale for the combination. ^[1] The product is marketed by Viatris (formerly Meda and Mylan) and is a prescription medicine.

Randomized controlled trials have compared the combination against its individual ingredients and placebo. In children with allergic rhinitis, the combination provided greater and faster symptom relief than fluticasone propionate alone, ^[2] and controlled trials in children with seasonal allergic rhinitis found it improved nasal and eye symptoms and quality of life compared with placebo. ^[3] A systematic review concluded that the combination gives more effective and more rapid relief of the full range of nasal and ocular symptoms than either intranasal azelastine or fluticasone used alone. ^[1]

A notable feature is speed of onset; the combination tends to bring symptoms under control faster than an intranasal steroid by itself, because the antihistamine component begins to act quickly while the steroid builds sustained anti-inflammatory control. ^[1]

Because it is delivered to the nose with limited absorption into the body, side effects are generally local, such as an unpleasant taste, mild nosebleeds, or nasal irritation. ^[1] It is a prescription-only nasal spray used once or twice daily as directed.

This is a prescription nasal spray and side effects are mostly local. Many people notice a bitter taste right after spraying, which improves if you keep your head tilted forward and do not sniff hard. Nosebleeds, nasal stinging or dryness, and headache can happen, and azelastine can cause some drowsiness. Long-term steroid spray use is generally safe but can occasionally irritate or, rarely, perforate the nasal septum, so aim the spray away from the septum. It works best used every day rather than only when symptoms flare.

This combination was developed as a novel single-device nasal spray, formulated to deliver the antihistamine azelastine and the corticosteroid fluticasone propionate together in one actuation, a formulation designated MP-AzeFlu. Its individual components were long-established: azelastine as an intranasal and ophthalmic antihistamine and fluticasone propionate as a widely used intranasal glucocorticoid. Brought forward by Meda Pharmaceuticals, the fixed-dose combination received U.S. Food and Drug Administration approval in 2012 under the brand name Dymista for the treatment of allergic rhinitis. It was positioned on evidence that the paired formulation relieves symptoms more fully and more quickly than either agent used alone.

The azelastine and fluticasone combination is highly regarded for moderate-to-severe allergic rhinitis, frequently cited in guidelines and meta-analyses as more effective than either an intranasal antihistamine or an intranasal steroid on its own. Clinicians value the pairing of azelastine's rapid symptom relief with fluticasone's sustained control of underlying inflammation, delivered conveniently from a single spray. Pooled trial data show meaningful improvements in nasal and ocular symptom scores and in quality of life, with a tolerability profile comparable to its components. It is often reached for when single-agent sprays have not brought a patient's hay fever fully under control.